Islam, M Ashequl <br/><br/>
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).  [electronic resource] 

 -  The American journal of cardiology  Nov 2002 
 - 916-21 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0002-9149 
<br/><br/><label>Standard No.: </label>10.1016/s0002-9149(02)02653-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--therapeutic use<br/>Blood Vessel Prosthesis Implantation<br/>Coronary Angiography--adverse effects<br/>Creatine Kinase--blood<br/>Creatine Kinase, MB Form<br/>Double-Blind Method<br/>Drug Evaluation<br/>Endpoint Determination<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Incidence<br/>Isoenzymes--blood<br/>Male<br/>Myocardial Ischemia--epidemiology<br/>North America--epidemiology<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--therapeutic use<br/>Stents<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome